|
EP2389362B1
(en)
|
2009-01-21 |
2019-12-11 |
Oryzon Genomics, S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
|
EP2480528B1
(en)
|
2009-09-25 |
2018-08-29 |
Oryzon Genomics, S.A. |
Lysine specific demethylase-1 inhibitors and their use
|
|
WO2011042217A1
(en)
|
2009-10-09 |
2011-04-14 |
Oryzon Genomics S.A. |
Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
|
|
WO2011106106A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
|
|
US9616058B2
(en)
|
2010-02-24 |
2017-04-11 |
Oryzon Genomics, S.A. |
Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
|
|
US8722743B2
(en)
|
2010-04-19 |
2014-05-13 |
Oryzon Genomics S.A. |
Lysine specific demethylase-1 inhibitors and their use
|
|
WO2012013727A1
(en)
|
2010-07-29 |
2012-02-02 |
Oryzon Genomics S.A. |
Cyclopropylamine derivatives useful as lsd1 inhibitors
|
|
ES2674747T3
(es)
|
2010-07-29 |
2018-07-03 |
Oryzon Genomics, S.A. |
Inhibidores de demetilasa LSD1 basados en arilciclopropilamina y sus usos médicos
|
|
WO2012045883A1
(en)
|
2010-10-08 |
2012-04-12 |
Oryzon Genomics S.A. |
Cyclopropylamine inhibitors of oxidases
|
|
WO2012072713A2
(en)
|
2010-11-30 |
2012-06-07 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
|
|
EP2712315B1
(en)
|
2011-02-08 |
2021-11-24 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for myeloproliferative disorders
|
|
EA025529B1
(ru)
*
|
2011-08-09 |
2017-01-30 |
Такеда Фармасьютикал Компани Лимитед |
Циклопропанаминовое соединение
|
|
EP2768805B1
(en)
*
|
2011-10-20 |
2020-03-25 |
Oryzon Genomics, S.A. |
(hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
|
|
JP6046154B2
(ja)
*
|
2011-10-20 |
2016-12-14 |
オリソン ヘノミクス エセ． アー． |
Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物
|
|
HUE033380T2
(en)
|
2012-10-02 |
2017-11-28 |
Gilead Sciences Inc |
Inhibitors of histone demethylases
|
|
CA2887598A1
(en)
*
|
2012-10-12 |
2014-04-17 |
Takeda Pharmaceutical Company Limited |
Cyclopropanamine compound and use thereof
|
|
EP2740474A1
(en)
*
|
2012-12-05 |
2014-06-11 |
Instituto Europeo di Oncologia S.r.l. |
Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
|
|
MX2015011097A
(es)
|
2013-02-27 |
2016-03-09 |
Epitherapeutics Aps |
Inhibidores de histona desmetilasas.
|
|
EP3003301B1
(en)
|
2013-05-30 |
2021-02-24 |
Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas |
Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells
|
|
WO2015012515A1
(ko)
*
|
2013-07-25 |
2015-01-29 |
동아에스티 주식회사 |
벤즈아미드 유도체의 제조방법, 그의 제조에 사용되는 새로운 중간체 및 상기 중간체의 제조방법
|
|
CA2920257C
(en)
*
|
2013-08-06 |
2023-02-21 |
Imago Biosciences Inc. |
Kdm1a inhibitors for the treatment of disease
|
|
DK3105218T3
(da)
*
|
2014-02-13 |
2019-11-04 |
Incyte Corp |
Cyclopropylaminer som lsd1-inhibitorer
|
|
TWI720451B
(zh)
|
2014-02-13 |
2021-03-01 |
美商英塞特控股公司 |
作為lsd1抑制劑之環丙胺
|
|
TW201613860A
(en)
*
|
2014-02-13 |
2016-04-16 |
Incyte Corp |
Cyclopropylamines as LSD1 inhibitors
|
|
US9527835B2
(en)
|
2014-02-13 |
2016-12-27 |
Incyte Corporation |
Cyclopropylamines as LSD1 inhibitors
|
|
CN104042616B
(zh)
*
|
2014-02-20 |
2016-08-24 |
复旦大学附属眼耳鼻喉科医院 |
赖氨酸特异性去甲基化酶1抑制剂的应用
|
|
MY180575A
(en)
|
2014-04-11 |
2020-12-02 |
Takeda Pharmaceuticals Co |
Cyclopropanamine compound and use thereof
|
|
EA036672B8
(ru)
|
2014-05-01 |
2021-01-13 |
Селджен Квонтисел Рисёрч, Инк. |
Ингибиторы лизин-специфической деметилазы-1
|
|
WO2016007727A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as lsd1 inhibitors
|
|
WO2016007722A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as lsd1 inhibitors
|
|
US9695168B2
(en)
|
2014-07-10 |
2017-07-04 |
Incyte Corporation |
Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
|
|
WO2016007736A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Imidazopyrazines as lsd1 inhibitors
|
|
EA201790154A1
(ru)
|
2014-08-27 |
2017-08-31 |
Джилид Сайэнс, Инк. |
Соединения и способы для ингибирования гистоновых деметилаз
|
|
WO2016055935A1
(en)
*
|
2014-10-06 |
2016-04-14 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
|
|
EA039196B1
(ru)
*
|
2014-10-08 |
2021-12-16 |
Инсайт Корпорейшн |
Циклопропиламины в качестве ингибиторов lsd1
|
|
WO2016123387A1
(en)
*
|
2015-01-30 |
2016-08-04 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
BR112017017074A2
(pt)
|
2015-02-12 |
2018-04-10 |
Imago Biosciences Inc |
Compostos; sal; bis-tosilatos de n-((s)-5-((1r,2s)-2-(4- fluorofenil)ciclopropilamino)-1-(4-metilpiperazin-1- il)-1-oxopentan-2-il)-4-(1h-1,2,3-triazol-1-il)benzamida; sal de tosilato de um composto; sal de bis- tosilato de um composto; compostos, sais, polimorfos ou solvatos; composições farmacêuticas, método para inibição de kdm1a; métodos para tratamento de uma doença mediada por kdm1a ou globina; método para atingir um efeito em um paciente; método para inibir pelo menos uma função de kdm1a
|
|
PE20180455A1
(es)
|
2015-04-03 |
2018-03-05 |
Incyte Corp |
Compuestos heterociclicos como inhibidores de lsd1
|
|
EP3286172B1
(en)
|
2015-04-23 |
2019-06-12 |
Constellation Pharmaceuticals, Inc. |
Lsd1 inhibitors and uses thereof
|
|
EP3090998A1
(en)
|
2015-05-06 |
2016-11-09 |
F. Hoffmann-La Roche AG |
Solid forms
|
|
KR20180011331A
(ko)
|
2015-06-12 |
2018-01-31 |
오리존 지노믹스 에스.에이. |
Lsd1 억제제와 관련된 바이오마커 및 그의 용도
|
|
WO2017013061A1
(en)
|
2015-07-17 |
2017-01-26 |
Oryzon Genomics, S.A. |
Biomarkers associated with lsd1 inhibitors and uses thereof
|
|
UA126277C2
(uk)
*
|
2015-08-12 |
2022-09-14 |
Інсайт Корпорейшн |
Солі інгібітору lsd1
|
|
EP3341353A1
(en)
|
2015-08-27 |
2018-07-04 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
|
WO2017079476A1
(en)
*
|
2015-11-05 |
2017-05-11 |
Mirati Therapeutics, Inc. |
Lsd1 inhibitors
|
|
WO2017091592A1
(en)
|
2015-11-25 |
2017-06-01 |
Genentech, Inc. |
Substituted benzamides useful as sodium channel blockers
|
|
WO2017097865A1
(en)
*
|
2015-12-07 |
2017-06-15 |
Istituto Europeo Di Oncologia |
Combination of caloric restriction (cr) or igf1/insulin receptor inhibitor with lsd1 inhibitor
|
|
MX384792B
(es)
|
2015-12-29 |
2025-03-14 |
Mirati Therapeutics Inc |
Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
|
|
WO2017114497A1
(en)
|
2015-12-30 |
2017-07-06 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|
|
WO2017157813A1
(en)
|
2016-03-15 |
2017-09-21 |
F. Hoffmann-La Roche Ag |
Combinations of lsd1 inhibitors for the treatment of hematological malignancies
|
|
WO2017157825A1
(en)
|
2016-03-15 |
2017-09-21 |
F. Hoffmann-La Roche Ag |
Combinations of lsd1 inhibitors for use in the treatment of solid tumors
|
|
JP2019512546A
(ja)
*
|
2016-03-16 |
2019-05-16 |
オリゾン・ゲノミクス・ソシエダッド・アノニマ |
Ｋｄｍ１ａ標的会合を決定するための方法、およびそれに有用な化学プローブ
|
|
CN107200706A
(zh)
*
|
2016-03-16 |
2017-09-26 |
中国科学院上海药物研究所 |
一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途
|
|
CN109071426A
(zh)
|
2016-03-30 |
2018-12-21 |
基因泰克公司 |
取代的苯甲酰胺及其使用方法
|
|
MA44725A
(fr)
|
2016-04-22 |
2019-02-27 |
Incyte Corp |
Formulations d'un inhibiteur de lsd1
|
|
CN107459476B
(zh)
*
|
2016-06-03 |
2022-06-24 |
中国科学院上海药物研究所 |
反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途
|
|
PL3307267T3
(pl)
|
2016-06-10 |
2019-10-31 |
Oryzon Genomics Sa |
Leczenie stwardnienia rozsianego
|
|
WO2018020366A1
(en)
|
2016-07-26 |
2018-02-01 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Crystalline (r)-mandelate salt of (1r,2s)-2-phenylcyclopropylamine
|
|
SG10201610038SA
(en)
*
|
2016-07-29 |
2017-12-28 |
Apple Inc |
Systems and methods for management of asymmetrical multi-tapped battery packs
|
|
US11390590B2
(en)
|
2016-08-16 |
2022-07-19 |
Imago Biosciences, Inc. |
Methods and processes for the preparation of KDM1A inhibitors
|
|
BR112019007763A2
(pt)
|
2016-10-17 |
2019-07-02 |
Genentech Inc |
composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção
|
|
US20190256930A1
(en)
|
2016-11-03 |
2019-08-22 |
Oryzon Genomics, S.A. |
Biomarkers for determining responsiveness to lsd1 inhibitors
|
|
WO2018083138A1
(en)
|
2016-11-03 |
2018-05-11 |
Oryzon Genomics, S.A. |
Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
|
|
US20200069677A1
(en)
|
2016-12-09 |
2020-03-05 |
Constellation Pharmaceuticals, Inc. |
Markers for personalized cancer treatment with lsd1 inhibitors
|
|
KR102576586B1
(ko)
*
|
2017-01-24 |
2023-09-11 |
씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 |
Lsd1 억제제 및 그의 제조방법과 용도
|
|
US10793550B2
(en)
|
2017-03-24 |
2020-10-06 |
Genentech, Inc. |
4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
|
|
US11918580B2
(en)
|
2017-04-26 |
2024-03-05 |
Istituto Europeo Di Oncologia S.R.L. |
Use of a combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer
|
|
CN110740991B
(zh)
|
2017-05-26 |
2023-07-04 |
大鹏药品工业株式会社 |
新型联苯化合物或其盐
|
|
TWI770925B
(zh)
|
2017-05-26 |
2022-07-11 |
日商大鵬藥品工業股份有限公司 |
使用有新穎聯苯化合物之抗腫瘤效果增強劑
|
|
TWI749235B
(zh)
|
2017-05-31 |
2021-12-11 |
日商大鵬藥品工業股份有限公司 |
基於insm1表現之lsd1抑制劑之治療效果的預測方法
|
|
KR20180134675A
(ko)
*
|
2017-06-09 |
2018-12-19 |
한미약품 주식회사 |
시클로프로필아민 유도체 화합물 및 이의 용도
|
|
JP2020152641A
(ja)
*
|
2017-07-07 |
2020-09-24 |
国立研究開発法人理化学研究所 |
リジン特異的脱メチル化酵素１阻害活性を有する新規化合物、その製造方法及びその用途
|
|
CN110996949A
(zh)
|
2017-08-03 |
2020-04-10 |
奥瑞泽恩基因组学股份有限公司 |
用于治疗行为改变的方法
|
|
TWI794294B
(zh)
|
2017-09-13 |
2023-03-01 |
南韓商韓美藥品股份有限公司 |
吡唑衍生化合物及其用途
|
|
WO2019068326A1
(en)
|
2017-10-05 |
2019-04-11 |
Université D'aix-Marseille |
INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
|
|
KR20190040763A
(ko)
|
2017-10-11 |
2019-04-19 |
한미약품 주식회사 |
피라졸로피리딘 유도체 화합물 및 이의 용도
|
|
KR20190040783A
(ko)
|
2017-10-11 |
2019-04-19 |
한미약품 주식회사 |
라이신 특이적 데메틸라제-1 억제제로서의 피라졸 유도체
|
|
WO2019083971A1
(en)
|
2017-10-23 |
2019-05-02 |
Children's Medical Center Corporation |
METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY
|
|
WO2019109095A1
(en)
*
|
2017-12-01 |
2019-06-06 |
Beth Israel Deaconess Medical Center, Inc. |
Arsenic trioxide and retinoic acid compounds for treatment of idh2-associated disorders
|
|
CN108107199B
(zh)
*
|
2017-12-21 |
2019-02-12 |
广州市进德生物科技有限公司 |
一种酶化学发光法测定尿酸的检测试剂盒
|
|
JP2021514980A
(ja)
|
2018-02-26 |
2021-06-17 |
ジェネンテック， インコーポレイテッド |
疼痛及び関連病態に対するピリジン−スルホンアミド化合物及びその使用
|
|
CN111936494A
(zh)
|
2018-03-30 |
2020-11-13 |
豪夫迈·罗氏有限公司 |
作为钠通道抑制剂的取代的氢-吡啶并-吖嗪
|
|
ES2977656T3
(es)
|
2018-05-11 |
2024-08-28 |
Imago Biosciences Inc |
Inhibidores de KDM1A para el tratamiento de enfermedades
|
|
TW202003490A
(zh)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
|
CA3106484C
(en)
*
|
2018-07-20 |
2024-06-25 |
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. |
A salt of an lsd1 inhibitor and its crystal form
|
|
WO2020047198A1
(en)
|
2018-08-31 |
2020-03-05 |
Incyte Corporation |
Salts of an lsd1 inhibitor and processes for preparing the same
|
|
CN112672994B
(zh)
*
|
2018-09-13 |
2022-09-13 |
南昌弘益药业有限公司 |
作为lsd1抑制剂的杂螺环类化合物及其应用
|
|
US11649245B2
(en)
|
2018-09-13 |
2023-05-16 |
Helioeast Pharmaceutical Co., Ltd. |
Cyclopropylamine compound as LSD1 inhibitor and use thereof
|
|
WO2020117972A1
(en)
*
|
2018-12-04 |
2020-06-11 |
The Board Of Regents Of The University Of Texas System |
Therapeutics targeting mutant adenomatous polyposis coli (apc) for the treatment of cancer
|
|
WO2020138398A1
(ja)
*
|
2018-12-28 |
2020-07-02 |
国立研究開発法人理化学研究所 |
リジン特異的脱メチル化酵素１を阻害する新規化合物、その製造方法及びその用途
|
|
WO2020159285A1
(ko)
|
2019-02-01 |
2020-08-06 |
한미약품 주식회사 |
이미다조피리딘 유도체 화합물 및 이의 용도
|
|
EP3907225A4
(en)
*
|
2019-02-01 |
2022-09-14 |
Hanmi Pharm. Co., Ltd. |
COMPOUNDS DERIVED FROM IMIDAZOPYRIDINE AND THEIR USE
|
|
JP7536316B2
(ja)
|
2019-03-20 |
2024-08-20 |
オリソン ヘノミクス，ソシエダ アノニマ |
境界性パーソナリティ障害の処置方法
|
|
US20220151999A1
(en)
|
2019-03-20 |
2022-05-19 |
Oryzon Genomics, S.A. |
Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
|
|
JP2022546908A
(ja)
|
2019-07-05 |
2022-11-10 |
オリゾン・ゲノミクス・ソシエダッド・アノニマ |
Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法
|
|
CN114502561B
(zh)
*
|
2019-09-29 |
2023-12-26 |
南昌弘益药业有限公司 |
Lsd1抑制剂
|
|
CN115835795A
(zh)
*
|
2020-05-28 |
2023-03-21 |
耐克创新有限合伙公司 |
包括流体移动控制器和可调节足部支撑压力的足部支撑系统
|
|
EP3964204A1
(en)
|
2020-09-08 |
2022-03-09 |
Université d'Aix-Marseille |
Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues
|
|
CN115485282B
(zh)
*
|
2021-02-09 |
2025-09-09 |
南昌弘益药业有限公司 |
一种氧氮杂螺环化合物、其盐型及其晶型
|
|
WO2022214303A1
(en)
|
2021-04-08 |
2022-10-13 |
Oryzon Genomics, S.A. |
Combinations of lsd1 inhibitors for treating myeloid cancers
|
|
WO2022267495A1
(zh)
*
|
2021-06-22 |
2022-12-29 |
南昌弘益药业有限公司 |
含氮氧杂螺环类化合物及其应用
|
|
CN113512031B
(zh)
*
|
2021-07-01 |
2024-01-30 |
都创(上海)医药开发有限公司 |
一种lsd1酶抑制剂tak-418中间体化合物制备方法
|
|
GB202115017D0
(en)
|
2021-10-20 |
2021-12-01 |
Univ London Queen Mary |
Sequential treatments and biomarkers to reverse resistance to kinase inhibitors
|
|
US20240418723A1
(en)
|
2021-10-20 |
2024-12-19 |
Queen Mary University Of London |
Sequential treatments and biomarkers to reverse resistance to kinase inhibitors
|
|
CN119497613A
(zh)
|
2022-05-09 |
2025-02-21 |
奥莱松基因组股份有限公司 |
使用lsd1抑制剂治疗nf1-突变肿瘤的方法
|
|
JP2025516647A
(ja)
|
2022-05-09 |
2025-05-30 |
オリゾン・ゲノミクス・ソシエダッド・アノニマ |
Ｌｓｄ１阻害薬を用いる悪性末梢神経鞘腫（ｍｐｎｓｔ）の治療法
|
|
JP2025538876A
(ja)
|
2022-11-24 |
2025-12-02 |
オリゾン・ゲノミクス・ソシエダッド・アノニマ |
がん治療のためのｌｓｄ１阻害薬とメニン阻害薬の組合せ
|
|
WO2024229406A1
(en)
|
2023-05-04 |
2024-11-07 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
CN117164465B
(zh)
*
|
2023-09-04 |
2025-07-01 |
郑州大学 |
一种苯基环丙胺类化合物及其制备方法和应用
|
|
TW202530228A
(zh)
|
2023-10-12 |
2025-08-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|